Search research articles
Contact Us
Filters
Showing results (231-240 of 275) with videos related to
Page
of 28
Sort By:
Investigational New Drugs
|
May 1, 1991
Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. A Southwest Oncology Group trial
S A Taylor, J Crowley, F S Vogel, et al.
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research
|
January 1, 1992
The int-2 gene product acts as a growth factor and substitutes for basic fibroblast growth factor in promoting the differentiation of a normal mouse mammary epithelial cell line
T Venesio, D Taverna, N E Hynes, et al.
Breast Cancer Research and Treatment
|
February 27, 2003
A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer
David M Loesch, Lina Asmar, Vikki A Canfield, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 1990
c-erbB-2 protein expression in node negative breast cancer
J Richner, H A Gerber, G W Locher, et al.
Blood
|
June 20, 1998
A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031)
J E Godwin, K J Kopecky, D R Head, et al.
Cancer Treatment Reports
|
September 1, 1986
Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study
G R Weiss, J Crowley, D D Von Hoff, et al.
American Journal of Clinical Oncology
|
October 1, 1987
A phase II trial of vinblastine in patients with advanced or recurrent endometrial carcinoma. A Southwest Oncology Group Study
J T Thigpen, R Kronmal, S Vogel, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
November 7, 2012
Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets
Simon Wöhrle, Christine Henninger, Olivier Bonny, et al.
Elife
|
January 14, 2017
NADPH oxidase-mediated redox signaling promotes oxidative stress resistance and longevity through <i>memo-1</i> in <i>C. elegans</i>
Collin Yvès Ewald, John M Hourihan, Monet S Bland, et al.
Investigational New Drugs
|
May 1, 1993
Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma. A Southwest Oncology Group study
M E Marshall, M K Wolf, E D Crawford, et al.
Page
of 28
Search research articles
Search
Showing results (231-240 of 275) with videos related to
Sort By:
Page
of 28
Investigational New Drugs
|
May 1, 1991
Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. A Southwest Oncology Group trial
S A Taylor, J Crowley, F S Vogel, et al.
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research
|
January 1, 1992
The int-2 gene product acts as a growth factor and substitutes for basic fibroblast growth factor in promoting the differentiation of a normal mouse mammary epithelial cell line
T Venesio, D Taverna, N E Hynes, et al.
Breast Cancer Research and Treatment
|
February 27, 2003
A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer
David M Loesch, Lina Asmar, Vikki A Canfield, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 1990
c-erbB-2 protein expression in node negative breast cancer
J Richner, H A Gerber, G W Locher, et al.
Blood
|
June 20, 1998
A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031)
J E Godwin, K J Kopecky, D R Head, et al.
Cancer Treatment Reports
|
September 1, 1986
Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study
G R Weiss, J Crowley, D D Von Hoff, et al.
American Journal of Clinical Oncology
|
October 1, 1987
A phase II trial of vinblastine in patients with advanced or recurrent endometrial carcinoma. A Southwest Oncology Group Study
J T Thigpen, R Kronmal, S Vogel, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
November 7, 2012
Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets
Simon Wöhrle, Christine Henninger, Olivier Bonny, et al.
Elife
|
January 14, 2017
NADPH oxidase-mediated redox signaling promotes oxidative stress resistance and longevity through <i>memo-1</i> in <i>C. elegans</i>
Collin Yvès Ewald, John M Hourihan, Monet S Bland, et al.
Investigational New Drugs
|
May 1, 1993
Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma. A Southwest Oncology Group study
M E Marshall, M K Wolf, E D Crawford, et al.
Page
of 28